ABSTRACT Background. The American Joint Committee on Cancer (AJCC) stage III classification of oral cavity squamous cell carcinoma (OCSCC) represents a heterogeneous group of patients with early local disease with regional metastases (T1N1 and T2N1) and advanced local disease with or without regional metastasis (T3N0 and T3N1). Objective. The aim of this study was to evaluate prognostic heterogeneity in the stage III category. Methods and Patients. An international retrospective multicenter study of 1815 patients who were treated for OCSCC from 2003 to 2011.
could be combined in future revisions of the nodal staging system to enhance prognostic accuracy.
Oral cavity squamous cell carcinoma (OCSCC) is the eighth most common cancer worldwide. 1 The American Joint Committee on Cancer (AJCC) Staging Manual categorizes early OCSCC disease as stage I or II, and locally advanced disease or distance metastasis as stage IV. Stage III disease represents a heterogeneous group, composed of patients with early local disease with regional metastases (T1N1 and T2N1) and patients with T3 disease with (N1) or without (N0) regional metastasis. 2 Although the simplicity and consistency across subsites of the current AJCC staging for head and neck cancer promotes clinical utility, it is widely acknowledged that the prognostic performance is suboptimal in selected subgroups. [3] [4] [5] [6] Ideally, a staging system distinguishes prognostic categories that are internally homogeneous; however, our clinical experience suggests that the stage III classification for oral cancer encompasses a wide spectrum of disease severity with variable prognoses.
In this international, multicenter, pooled study, we aimed to evaluate prognostic heterogeneity in the stage III category of OCSCC. We show an improvement in patient outcome stratification based on a novel categorization of stage III compared with the previous one.
MATERIALS AND METHODS

Patient Population
Our study cohort comprised 1815 patients who were treated for OCSCC from 2003 to 2011 in seven cancer centers worldwide; patients with oropharyngeal disease were excluded. Relevant demographic and clinicopathological details are summarized in Table 1 . The study was approved by the local Institutional Review Board (IRB) committees. Patients ranged in age from 15 to 93 years, with a median of 54 years, and follow-up ranged from 6 to 116 months, with a median of 35 months.
Treatment
Treatment modalities included surgery alone (61 patients, 26 %), surgery and adjuvant radiotherapy (101 patients, 43 %), or surgery followed by chemoradiotherapy (74 patients, 31 %). Adjuvant cetuximab was administered to 28 patients (11 %). All patients underwent a standardized neck dissection involving levels I-III, I-IV, or I-V, as described by the American Head and Neck Society. 7 The type of neck dissection was prespecified in all patients prior to the operation. Elective neck dissection was performed in 147 patients (62 %), while 89 patients (38 %) underwent therapeutic neck dissection.
Data Entry, Patient Exclusions, and Statistical Methods
Data were entered into a commercially available spreadsheet (Microsoft Excel 2000, Microsoft Corporation, Seattle, WA, USA), and statistical analysis was performed using a computerized software package (JMP version 4.0, SAS Institute Inc., Cary, NC, USA; and SPSS, SPSS Inc. Chicago, IL, USA). The follow-up interval was calculated in months from the date of surgery to the date of last follow-up or death. Overall survival (OS) and disease-specific survival (DSS) rates were calculated using the Kaplan-Meier method, and univariate comparisons between groups were performed using concordance index (c statistic), a generalization of the area under the receiver operating characteristic curve that quantifies the proportion of all patient pairs for whom the predicted and observed survival outcomes are concordant. 8 A value of c = 0.5 indicates no predictive ability compared with chance alone, and a value of 1 indicates perfect discrimination. In general, a predictive model with a low AIC indicates a better model fit, and a high c statistic represents a better discrimination ability. 
Bilateral 3 (11) 9 (11) 18 (20) 10 (28) Nodal yield \18 6 (21) 11 (14) 13 (14) 3 (8) (20) 19 (52) (iii) Comparison with multivariable models with and without the covariate of interest, using a likelihood ratio test to determine whether model fit was significantly improved. A p value B0.05 was considered significant, and significant factors were entered into multivariate analysis using the Cox proportional hazards model.
RESULTS
To assess differences in outcome, patients with stage III OCSCC were divided into four groups according to the primary tumor (T) and regional lymph node (N) classification: T1N1 (n = 29 patients, 12 %), T2N1 (n = 80 patients, 34 %), T3N0 (n = 91 patients, 39 %), and T3N1 (n = 36 patients, 15 %). Table 2 presents the clinical and demographical data of patients with OCSCC stage III (n = 236). We first investigated the differences in demographic and clinical characteristics between the four groups. Male sex was more prevalent in patients with T3 than combined T1 and T2 classification (82 vs. 65 %; p = 0.02). Patients in the T2N1 group were younger (mean age 50.8 ± 1.4 vs. 55.8 ± 2.3 years; p = 0.03) than in the other classification groups combined. No differences between the groups in the rates of depth of invasion or positive surgical margins were observed.
We identified differences in treatment regimens between classification groups: T3N1 patients underwent postoperative radiotherapy with or without chemotherapy more frequently than patients in the other stage III groups combined (98 and 70 %, respectively; p \ 0.001).
Kaplan-Meier analysis of patients with stage III disease according to TNM groups is shown in Fig. 1 . The curves show better 5-year OS for patients with T1N1, T2N1, and T3N0 disease (71, 67, and 73 %, respectively) than for those with T3N1 disease (52 %). Similarly, stratifying stage III disease by T3N1 and T1-2N1/T3N0 revealed significantly worse outcomes for T3N1 patients: DSS (p = 0.037) and OS (p = 0.036). Most importantly, multivariable models for stage III patients show significantly worse outcomes for T3N1 patients than for patients in the other stage III groups combined: DSS (HR 1.7, 95 % CI 1.16-4.12; p = 0.04) and OS (HR 2.12, 95 % CI 1.03-4.15; p = 0.01), as shown in Table 3 .
Next, we assessed whether T3N1 patients have similar prognosis as those in stage IVa (T4aN0-2, T1-3N2). Figure 2a and b compare OS and DSS of stage IVa patients with rates of the T3N1 group. Five-year OS and DSS for T3N1 patients were comparable with rates for the stage IVa subgroups (Fig. 2a , p = 0.89; and Fig. 2b, p = 0.78) . Similarly, multivariate analysis showed no significant differences between stage IVa and T3N1 patients. Furthermore, removal of T3N1 patients from the stage III category preserved the differences in prognosis between stages II and III (OS, p = 0.01; DSS, p = 0.04) (Fig. 2c, d) .
Through regression modeling, the staging system with the best prognostic discriminatory ability was then assessed through iterative statistical models and comparison of AIC To confirm our results, we repeated the multivariate analysis on an independent cohort of 255 pathologically staged III-IV patients who were treated in a single institution (National Cancer Center of Singapore, Singapore). Statistical analyses of this single-institution cohort showed that T3N1 patients had worse OS and DSS than other stage III patients (p = 0.002 and p = 0.001, respectively). Similar to the results of the current, larger cohort, we did not find significant differences in outcomes between T3N1 and stage IV patients.
DISCUSSION
The mainstay of treatment in oral cavity cancer is surgery. 10 Adjuvant treatment is administered to patients with early disease (staged as I-II) only in the presence of adverse pathological features. In contrast, in patients with advanced disease (staged as III-IV), or in the presence of positive lymph nodes, adjuvant treatment is usually indicated. Early disease is well-defined by limited local disease or the absence of metastatic lymph nodes (T1-2, N0). Nevertheless, stages III and IV entail heterogeneous groups, which may be characterized by limited local disease with extensive nodal metastases, locally advanced disease and no lymph node metastases, or locally advanced disease with nodal metastases.
11
Improvements in the sensitivity of imaging techniques, computerized tomography (CT), positron emission HR hazard ratio, CI confidence interval, ECS extracapsular spread, RT radiotherapy, CRT chemoradiation a p \ 0.05 tomography (PET), and ultrasound have augmented our ability to identify metastatic lymph nodes as small as 3 mm in size. [12] [13] [14] The result is an increase in the number of patients presenting with a single nodal metastasis. The presence of single lymph node metastases in patients with early local disease (T1-2) has been associated with poor outcome. [15] [16] [17] [18] [19] In the current study, we show for the first time that the presence of both single lymph node metastasis and a tumor larger than 4 cm (i.e., T3N1) predicts worse outcome than the other risk groups within the stage III category. Furthermore, our multivariate analysis shows that this group of patients has similar prognosis to that of patients staged as IVa, and that removal of T3N1 patients from the stage III category improved the statistical coherence of this group, while preserving the prognostic characteristics of stages II and IV.
Current National Comprehensive Cancer Network (NCCN) guidelines indicate adjuvant radiotherapy in patients with pT3, regardless of their nodal status. The addition of concurrent chemotherapy in such cases, in the absence of extracapsular spread or positive margins, is still equivocal and not under uniform consensus. Compared with radiotherapy alone, slight improvement in 5-year survival rates have been demonstrated after adjuvant concurrent chemoradiation therapy for advanced head and neck SCC. 20 However, due to the significant morbidity associated with intensification of adjuvant treatment, i.e., adding chemotherapy to radiotherapy, there is still considerable controversy over the pathological characteristics of the tumor that predict the need for more aggressive adjuvant treatment. 19 Re-stratifying patients with T3N1 classification to stage IVa can potentially assist in identifying patients with poor outcomes, and for whom concomitant adjuvant treatment may be needed. Further studies are required to determine whether these patients will benefit from concurrent chemoradiation therapy.
This study has some limitations of this study, i.e., the potential inconsistencies in surgical techniques and in the processing of pathological specimens, and the differences in treatment regimens. To address the matter of heterogeneity we performed an external validation using data from a single institute not included in our cohort. In that analysis we found that T3N1 classification remained a significant independent predictor of outcome and that T3N1 patients had worse OS and DSS compared with other stage III patients. Conversely, the significance of our heterogeneous cohort across multiple countries assures the broad applicability of our research findings worldwide and might facilitate the upstaging of T3N1 into stage IVa in diverse patient populations. 21 Due to the retrospective nature of the study, data regarding primary tumor site, smoking status, and alcohol exposure were not consistently available, and were therefore not included in the analysis.
CONCLUSIONS
Our data, derived from a multi-institutional international study that represents the largest and most detailed cohort of T3N1  T1N2  T2N2  T3N2  T4N0  T4N1 
